HESI News
Upcoming Events
Past Events
_________________________________________________
HESI Emerging Issues Survey – Request for Submissions
HESI invites you to electronically submit emerging scientific issues for potential program development. Click here to access Instructions for Electronic Submission of Emerging Issues for HESI Consideration and to download an interactive Emerging Issues Survey Form. (link on homepage)
HESI Announces Executive Director
HESI is please to announce that Michael P. Holsapple, Ph.D., A.T.S., has accepted the position of Executive Director of the ILSI Health and Environmental Sciences Institute (HESI). Click here for more information. (link on homepage)
HESI Genomics Committee Seeking Proposals by July 15, 2007
The HESI Genomics Committee is currently seeking proposals for new projects for possible adoption in 2008. We encourage all submissions. Click here for Details and a submission form. (link on homepage)
HESI at Eleventh International Congress of Toxicology – Montréal, Canada, July 15-19, 2007
HESI will co-sponsor a session entitled “Nanomaterials: Evaluating The Benefits And The Risks,” with the American College of Toxicology on July 19, 2007, as part of the Eleventh International Congress of Toxicology at the Palais des Congrès de Montréal, Montréal, Canada. The session will be chaired by HESI Executive Director, Dr. Michael Holsapple.
HESI’s Board of Trustees will also conduct its mid-year 2007 meeting immediately following the International Congress of Toxicology, enabling a number of HESI trustees to participate in the event, as well as the Nanomaterials session. HESI will also share information on its activities and programs via a booth in the Congress exhibition hall. (no link)
HESI Non-Clinical/Clinical Safety Correlations Meeting, Sept 20-21, 2007
The HESI Non-Clinical / Clinical Safety Correlations Technical Committee is hosting a workshop September 20-21, 2007 in Washington, DC to develop a better understanding of the extent to which toxicities manifested in preclinical animal studies correlate with those seen in clinical trials. Click here for further information. (link on homepage)
HESI Immunotoxicology Committee Meeting, Oct 1-3, 2007
The HESI Immunotoxicology Technical Committee is conducting an "Immunogenicity Roundtable" as part of a joint meeting on the "Nonclinical Safety Evaluation of Biopharmaceuticals," in Lyon, France, on October 1-3, 2007. Immunogenicity evaluation in preclinical vs clinical studies will be addressed, as will types and practical applications of immunogenicity assays. Case studies will be presented. The roundtable is part of the annual “Summer School in Immunotoxicology,” which will also include an International Conference on Harmonisation session. Click here for further information on the Roundtable and the joint meeting. (http://www.hesiglobal.org/Committees/TechnicalCommittees/Immunotox/)
HESI Genomics Committee Symposium, Nov 7-8, 2007
This November 7-8, 2007 meeting will feature the HESI Genomics Committee’s first public release of results from its four 2005-2007 research programs. The presentations will cover: a) insights into ‘noisy’ and ‘quiet’ baseline gene expression as evaluated in a novel database of control rodent microarray data from liver/kidney; b) results from a 6 week rodent cardiotoxicity study designed by the Committee to explore the relationship between traditional toxicity measures (e.g., histopathology and clinical chemistry) and more recent mechanistic/toxicity tools (e.g., gene microarray and cardiac troponin data); c) outputs from a multi-lab pilot studying using RT-PCR and microarray to identify gene sets capable of distinguishing direct and in-direct acting genotoxins; and finally, d) a report on the variation in applications of and perceptions about microarray technologies in different sectors and job categories according to the Committee’s online survey of over 100 scientists. Day 2 of the meeting will focus on identification of new research priorities for the Committee for 2008. The meeting will be held at the Westin Washington Hotel and is open to the public, however advance registration is required. Click here for registration forms and an agenda.
(http://www.hesiglobal.org/Committees/TechnicalCommittees/Genomics/Upcoming+Activities.htm)
HESI Weight of Evidence Project Symposium at SRA Meeting, Dec 9-12, 2007
The Risk Assessment Methodologies Technical Committee will present a symposium entitled, “Approaches to weight of evidence evaluation in risk assessment: A HESI Initiative” at the 2007 Society of Risk Analysis Annual Meeting, December 9-12 in San Antonio, TX. The symposium will summarize the proceedings of the committee’s December 2006 international, multi-sector workshop, which provided a public forum for the exchange of information on various approaches to weight of evidence analysis within the context of risk assessment. The symposium will consist of four talks, which will provide an introduction to the weight of evidence concept and methodologies, several different regulatory perspectives on the use of weight of evidence, recommendations for a research agenda, and some perspective and future directions for the HESI Weight of Evidence project. Click here for further information about this symposium and the committee activities.
(http://www.hesiglobal.org/Committees/TechnicalCommittees/RAM/)
HESI Developmental and Reproductive Toxicology Technical Committee Platform Sessions, June 24, 2007
The HESI Developmental and Reproductive Toxicology (DART) Technical Committee sponsored a platform session entitled “Application of Pharmacogenomics in Drug Development and Regulatory Science” at the 47th Annual Meeting of the Teratology Society, on June 24, 2007, in Pittsburgh, PA. This was the second such session sponsored by DART at the Teratology, following sponsorship at the 2006 meeting of a session on Regulatory Science. The committee will sponsor a session on vaccines at the 2008 meeting in Monterey, CA. Click here for further information on activities of the DART Technical Committee.
(www.hesiglobal.org/Committees/TechnicalCommittees/DART/)
HESI In Vitro Genetic Toxicity (IVGT) Testing Workshop, June 5-6, 2007
The HESI Emerging Issues Subcommittee on the Relevance and Follow-up of Positive Results in in Vitro Genetic Toxicity Testing (IVGT) held an international workshop June 5-6, 2007, in Washington, DC. The workshop was a follow-up to the subcommittee’s June, 2006 workshop, which examined ways to advance the basis for the interpretation of positive findings in in vitro assays, facilitate the development of follow-up testing strategies, and define criteria to determine the relevance to human health. The 2007 workshop participants discussed and expanded upon four potential sub-group topic areas, set goals and timelines, and worked to propose a path forward for the committee. The IVGT steering team is in the process of finalizing a workplan for the subcommittee and establishing membership for two main workgroups. Click here for more information on this committee.
(http://www.hesiglobal.org/Committees/EmergingIssues/ToxTesting/)
HESI Biomarkers Committee ‘Mini-Symposium’ at FDA, Apr 11, 2007
Senior leadership of the HESI Committee on Biomarkers of Toxicity presented an update on the Committee’s current and pending research programs on cardiac, testicular, and kidney biomarkers at FDA’s White Oak Headquarters on April 11, 2007. The session was attended by more than fifty FDA scientists from a variety of divisions. Click here to download abstracts from the presentations.
(http://www.hesiglobal.org/Committees/TechnicalCommittees/Biomarkers/default.htm)